Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av Vemurafenib och Obinutuzumab jämfört med Cladribine och Rituximab hos personer med hårcellsleukemi (HCL)

16 november 2026 uppdaterad av: Memorial Sloan Kettering Cancer Center

En randomiserad, multicenter, fas II-studie av Vemurafenib Plus Obinutuzumab vs. Cladribine Plus Rituximab hos patienter med tidigare obehandlad hårcellsleukemi (HCL)

The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

86

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Mark Geyer, MD
  • Telefonnummer: 646-608-3745

Studieorter

    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02115
        • Har inte rekryterat ännu
        • Dana Farber Cancer Institute
        • Kontakt:
          • Eric Winer, MD
          • Telefonnummer: (617) 632-6876
    • Minnesota
      • Rochester, Minnesota, Förenta staterna, 55905
        • Har inte rekryterat ännu
        • Mayo Clinic Cancer Center
        • Kontakt:
          • Sameer Parikh, M.B.B.S.
          • Telefonnummer: 507-218-0772
    • New Jersey
      • Basking Ridge, New Jersey, Förenta staterna, 07920
        • Rekrytering
        • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • Middletown, New Jersey, Förenta staterna, 07748
        • Rekrytering
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • Montvale, New Jersey, Förenta staterna, 07645
        • Rekrytering
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
    • New York
      • Commack, New York, Förenta staterna, 11725
        • Rekrytering
        • Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • Harrison, New York, Förenta staterna, 10604
        • Rekrytering
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • New York, New York, Förenta staterna, 10065
        • Rekrytering
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • Uniondale, New York, Förenta staterna, 11553
        • Rekrytering
        • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
    • Ohio
      • Columbus, Ohio, Förenta staterna, 43210
        • Rekrytering
        • Ohio State University
        • Kontakt:
          • Seema Bhat, MD
          • Telefonnummer: 614-293-3196

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patients must be ≥ 18 years of age

  • Histologically confirmed classical HCL by the enrolling institution

  • Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry. If patient is known to have negative BRAF mutation, repeat testing is advisable as well as discussion with the main study principal investigator.

  • Has not received any prior therapy for the disease

  • Patients who meet the standard treatment initiation criteria, as defined by ANC ≤1.0, Hgb ≤ 10.0 or PLT ≤100K

  • ECOG performance status of 0 - 2

  • Acceptable pre-study organ function during screening as defined as:

    • Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except in patients with known Gilbert's syndrome who may be enrolled if direct bilirubin ≤ 3 x ULN);
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; and
    • Serum creatinine ≤ 1.5x ULN
  • Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QTc, Bazett's formula) of < 480 msec

  • For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib and cladribine, and 18 months after discontinuation of rituximab and obinutuzumab

  • For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib

  • Negative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potential

Exclusion Criteria:

  • Have had previous treatment for HCL, including purine analogs, vemurafenib, rituximab, obinutuzumab, and other investigational agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed.

  • Known hypersensitivity to any of the study drugs.

  • Patients with known long QT syndrome or uncorrectable electrolyte abnormalities

  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.

  • Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody

    ° Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and take HBV viral prophylaxis such as entecavir.

  • Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)

  • Active uncontrolled infection, e.g. persistent bacteremia, supplemental oxygen or pressor supports, etc.

  • Live vaccination within 28 days of randomization

  • Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years

  • Malabsorption syndrome or other condition that precludes enteral route of administration

  • Patients with HCL variant (as defined by absence of expression of CD25)

  • Pregnant or lactating, or intending to become pregnant during the study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Vemurafenib plus Obinutuzumab

Patients assigned to the study arm will receive vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered on days 1, 8 and 15 during the cycle 2 and every 4 weeks during the cycle 3 and 4 of treatment.

Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.

Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.

Aktiv komparator: Standard treatment of Cladribine plus Rituximab

Patients assigned to the SOC arm will receive cladribine IV on days 1-5 concurrently with rituximab IV per week for 8 times, i.e., weekly x8 from day 1.

Cladribine IV on days 1-5 concurrently with rituximab.

Rituximab on days 1-5 concurrently with rituximab.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
incidences of ≥ grade 3 treatment-related toxicities
Tidsram: within 6 months of treatment

per CTCAE v5.0 within first 6 months from the start of the treatment to account delayed toxicities of the treatments

within 6 months of treatment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
complete remission
Tidsram: 2 years

Response will be determined by the Consensus Resolution response criteria.

Complete response (CR)

  • A morphological absence of hairy cells in the blood and bone marrow
  • A normalization of any organomegaly and cytopenias
2 years
partial response
Tidsram: 2 years

Partial response (PR)

°A normalization of cytopenias

°≥50% reduction in organomegaly and bone marrow hairy cells.

2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Jae Park, MD, Memorial Sloan Kettering Cancer Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 september 2024

Primärt slutförande (Beräknad)

9 september 2027

Avslutad studie (Beräknad)

9 september 2027

Studieregistreringsdatum

Först inskickad

13 augusti 2024

Först inskickad som uppfyllde QC-kriterierna

15 augusti 2024

Första postat (Faktisk)

20 augusti 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera